Scientists develop HIV vaccine that shows promise in human trials
An experimental HIV vaccine was well-tolerated and generated immune responses against the deadly virus in healthy human adults, scientists say.
The vaccine regimens evaluated in APPROACH – an early- stage clinical trial – are based on “mosaic” vaccines designed to induce immunological responses against a wide variety of HIV subtypes responsible for HIV infections globally, researchers said.
They found that different mosaic vaccine regimens were well-tolerated and capable of generating anti-HIV immune responses in healthy, HIV-negative adults.
Researchers found that the vaccine called Ad26.Mos.HIV was most protective in pre-clinical studies in animals elicited among the greatest immune responses in the study participants.
“A safe and effective HIV vaccine would be a powerful tool to reduce new HIV infections worldwide and help bring about a durable end to the HIV/AIDS pandemic,” said Anthony S Fauci, Director at National Institute of Allergy and Infectious Diseases (NIAID) in the US.
“By exploring multiple promising avenues of vaccine development research, we expand our opportunities to achieve these goals,” Fauci added.
Researchers randomly assigned 400 volunteers in the US, Rwanda, Uganda, South Africa and Thailand to receive one of seven experimental vaccine regimens or a placebo.
Participants received four vaccinations over 48 weeks: two doses of an initial, or “prime,” vaccine, followed …read more